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AN IN VITRO STUDY OF HUMAN FIBROBLAST CONTRACTILITY AND THE 
DIFFERENTIAL EFFECT OF TGF-b 1 AND TGF-b 3 ON FIBROBLAST 
CONTRACTION AND COLLAGEN SYNTHESIS 
 
 
 
 
Brian H. Campbell, M.S. 
 
 
University of Pittsburgh 
 
 
 
Skin, tendons, and other tissues can heal, but with formation of scar tissue, characterized 
by altered biochemical composition, distorted tissue architecture, and decreased mechanical 
properties compared to the normal tissues.  Excessive cellular contraction in wounds can lead to 
formation of scar tissue, whereas insufficient cellular contraction may impede wound closure.  In 
addition, although both TGF-b1 and TGF-b3 have been found to increase cellular contraction, 
only TGF-b3 has been shown to reduce formation of scar tissue in rat skin wounds.  Therefore, 
the overall objective of this project is to reduce the formation of scar tissue by regulating cellular 
contraction.  As part of this objective, this thesis project studies human fibroblast contractility 
 iv 
and the differential effect of TGF-b1 and TGF-b3 on human fibroblast contraction and collagen 
synthesis using in vitro models.  Either human skin or tendon fibroblasts were used in this 
project, depending on the nature of the specific study. 
 
Human tendon fibroblasts were found to contract in vitro and the degree of contraction 
was dependent on serum concentration.  Further, a multi-station culture force monitor (CFM) 
system was developed to characterize cellular contraction.  Using this system, human tendon 
fibroblasts were found to have a significantly lower maximum contraction force and a markedly 
different contraction pattern than human skin fibroblasts, illustrating the ability of this system to 
differentiate between cells from different tissues.  In addition, the effect of TGF-b1 and TGF-b3 
on cellular contraction and collagen synthesis of human skin fibroblasts was studied using the 
CFM system.  Both TGF-b1 and TGF-b3 were found to increase human fibroblast contraction 
and collagen synthesis, but TGF-b3 increased cellular contraction and collagen synthesis to a 
lesser extent than TGF-b1.   
 
 As there is great interest in improving the quality of healing tissue, these studies provide 
a foundation to further study the cellular and molecular mechanisms of tissue wound healing.  In 
addition, these findings suggest that TGF-b3 instead of TGF-b1 may be applied to regulate 
tendon fibroblast contraction, which may reduce formation of scar tissue in healing tendons.  
Future studies will continue to elucidate the relationship between cellular contraction and 
collagen synthesis.   
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1.0  INTRODUCTION 
 
 
 
 One of the goals in wound healing research is to develop a means to reduce scar tissue 
formation, thereby improving the quality and function of tissues following injury.  Many tissues, 
including skin and tendons, heal with scar tissue formation (1,2,3,4,5,6,7), which is characterized by 
varied biochemical composition, distorted tissue architecture, and decreased mechanical 
properties in comparison with the normal tissue.  Unlike adult skin, fetal skin can heal without 
scar formation (8,9,10,11,12), which results in a tissue that resembles the surrounding tissue in 
architecture, composition, and function.  Although the mechanisms for this healing response 
remain unclear, fibroblast contraction is thought to play an important role in the different healing 
responses of adult and fetal tissue (11). 
 
 To study cellular contraction, several in vitro models, i.e. thin silicone membrane 
(TSM) and cell populated collagen gel (CPCG), have been developed.  The TSM model has been 
used to estimate cellular forces present during cell division(13).  Using the CPCG model, early 
fetal skin fibroblasts were found to be less contractile than adult skin fibroblasts (12), suggesting 
that excessive cellular contraction may contribute to formation of scar tissue.  In spite of the 
studies on skin fibroblast contraction, only a few studies have investigated the contractility of 
tendon fibroblasts (14,15,16).  Additional studies are needed to investigate the potential role of 
cellular contraction in other cellular responses necessary for wound healing.  For example, 
collagen synthesis is needed for the maintenance and repair of tissues; however, an overproduced 
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collagen matrix is a characteristic of scar tissue (17).  Further, growth factors, such as TGF-β1 and 
TGF-β3, have been shown to increase contraction and collagen synthesis of human skin 
fibroblasts (18), but interestingly, only TGF-β3 reduces the formation of scar tissue in rat skin 
wounds (17).  Therefore, the overall goal of this thesis project was to enhance tissue healing 
quality by reducing scar tissue formation.  Specifically, we are interested in investigating human 
fibroblast contractility and the differential effect of TGF-β1 and TGF-β3 on fibroblast 
contraction and collagen synthesis. 
 
 This thesis is organized as follows.  Chapter 2 is a brief review of the relevant literature 
on tissue wound healing, transforming growth factor-β, cellular contraction, in vitro models used 
to study cellular contraction, and the relationship of cellular contraction and collagen synthesis.  
Chapter 3 presents the specific aims of this thesis.  In chapter 4, the TSM and CPCG models 
were used to determine whether human tendon fibroblasts are contractile.  Chapter 5 describes 
the development of a new multi-station culture force monitor (CFM) system that was then used 
to quantify and compare contraction of human skin and tendon fibroblasts.  Chapter 6 quantifies 
and compares the effect of TGF-β1 and TGF-β3 on human fibroblast contraction and collagen 
synthesis.  Finally, chapter 7 summarizes the findings of the thesis studies and discusses the 
implications that these findings have on tissue wound healing in general, and scar tissue in 
particular.  Lastly, the future directions of this project will be discussed. 
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2.0  LITERATURE REVIEW 
 
 
 
 
2.1  Tissue Wound Healing 
 
 
 
 The healing response of tissues consists of four phases (4).  The first phase involves an 
inflammatory response that initiates the healing cascade.  The second phase is comprised of 
restoration of blood supply via angiogenesis to restore blood supply and the beginning of the 
repair process with migration and proliferation of fibroblasts into the injured site.  Wound 
contraction and synthesis of collagen and proteoglycans are the major events of the third phase.  
In the fourth phase, the cells remodel the extracellular matrix (4).  Even with this highly 
orchestrated and intricate wound healing process, many tissues, including skin and tendons, heal 
with formation of scar tissue (1,2,3,4,5,6,7).  Not only does scar tissue have altered tissue architecture 
and composition, but in many cases, it may also impede the functions of the healing tissue.  For 
example, a study found that scar tissue significantly decreases the range of motion of the 
interphalangeal joints after the rupture of a flexor tendon in a rabbit model (19). 
 
 Therefore, it is highly desired to reduce the formation of scar tissue, thereby improving 
the quality and function of tissues following injury.  Previous studies have found that fetal skin 
wounds, unlike adult wounds, can heal without scar formation (9,10,11,20,21,22,23).  It has been proposed 
that the scar-less formation of skin wounds is an intrinsic property of fetal fibroblasts (11).  For 
example, an incision into fetal skin implanted subcutaneously in adult athymic mice healed 
without scar formation, due to the absence of adult fibroblasts.  However, incisions to fetal skin 
implanted cutaneously allowed for the adult fibroblasts to migrate into the wound site, resulting 
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in formation of scar tissue (11).  Another study found that fetal tendons healed three times faster 
and without scar formation or loss of function in contrast to similarly injured adult tendons (24).  
These findings suggest that if the phenotypic responses of adult fibroblasts can be regulated to 
simulate those of fetal fibroblasts, then the formation of scar tissue in adults may be significantly 
reduced and result in near normal tissue function.   
 
 
 
2.2  Transforming Growth Factor-β (TGF-β) 
 
 
 
One factor that potentially affects the phenotypic differences between fetal and adult 
tissue healing is the growth factor profile (10,11,21,22,23).  Of particular interest is transforming growth 
factor-β (TGF-β), which exists as three different isoforms in mammals: TGF-β1, TGF-β2, and 
TGF-β3 (25).  Since adult tissue, unlike fetal tissue, heals with scar formation (11,26) and TGF-β1 is 
present in the adult but it is not detected in fetal skin wounds (10,11,21), this suggests that TGF-β1 is 
one of the major growth factors contributing to the formation of scar tissue in adult skin wounds.  
In one study, polyvinyl alcohol (PVA) sponges containing 0.01 to 10 ng of TGF-β (the TGF-β 
isoform used was not specified in this study) were subcutaneously implanted in fetal rabbits.  
The implants were found to contain an increased number of fibroblasts and inflammatory cells, 
as well as an increased amount of collagen deposition compared with those treated with the 
controls, which were PVA sponges with only the TGF-β vehicle (20).  These findings suggest that 
TGF-β can induce fetal fibroblasts to respond similarly to that of adult fibroblasts and form scar 
tissue.   
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In another study, a piece of human fetal skin was implanted subcutaneously into adult 
nude mice (21).  Interestingly, implantation of 0.01 to 10 µg of TGF-β1 in a cellulose pellet under 
the fetal skin resulted in formation of scar tissue in amounts proportional to the applied dosage of 
TGF-β1 (21), providing additional evidence that TGF-β1 is involved in formation of scar tissue.  
In rabbit flexor tendons, the levels of TGF-β1 and its receptor expression were both elevated in 
healing tendons compared to normal tendons (27,28), suggesting that the fibroblasts in the healing 
tendon are most likely stimulated by the elevated levels of TGF-β1.   
 
The effects of all three TGF-β isoforms on skin wounds using Sprague-Dawley rats were 
investigated in another study (17).  TGF-β1, TGF-β2, TGF-β3, or neutralizing antibodies to the 
TGF-β isoforms were injected into the wound margins.  Injections of either TGF-β1 or TGF-β2 
resulted in increased collagen deposition and similar wound architecture compared with controls, 
which are wounds without the TGF-β injection (17).  Most noteworthy was that injection of TGF-
β3 resulted in reduced collagen deposition and a substantial improvement in the wound 
architecture compared with control wounds (17).  Further, application of neutralizing antibodies to 
TGF-β1 and TGF-β2 also reduced the formation of scar tissue (17).  These findings indicate that 
the TGF-β isoforms differentially affect collagen deposition and wound architecture.  Therefore, 
TGF-β1 is again implicated to contribute to formation of scar tissue, whereas TGF-β3 may 
actually reduce scar tissue.  In addition to these findings, another study investigated the effects of 
a neutralizing antibody to TGF-β1 on the postoperative range of motion at the proximal and 
distal interphalangeal joints after transection of the flexor tendon in rabbits (19).  This study found 
that treatment with an antibody to TGF-β1 significantly increased range of motion compared 
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with the untreated group.  Therefore, TGF-β1 may not only impact the biochemical composition 
and architecture of wounds, but also the function of healing tissues.   
 
These findings suggest that TGF-β1 and TGF-β3 can induce differential responses at the 
tissue level.  Further, at the cellular level, all TGF-β isoforms generally stimulate fibroblast 
growth (25), and both TGF-β1 and TGF-β3 were found to increase human skin fibroblast DNA 
synthesis and collagen production (18).  TGF-β is known to be an important growth factor for 
normal development and repair processes (25).  Since these studies indicate that the TGF-β 
isoforms may differentially affect tissue healing, particularly the formation of scar tissue, these 
TGF-β isoforms may also differentially regulate cellular contraction, a necessity for wound 
closure and healing (26). 
 
 
 
2.3  Cellular Contraction 
 
 
 
 Wound closure is mediated by cellular contraction (26), which is the force a cell exerts on 
the extracellular matrix.  The actin cytoskeleton was found to be a necessary component of 
cellular contraction (29).  In addition, the interaction between actin and myosin is involved in 
cellular contraction since myosin light chain kinase inhibitors were found to decrease cellular 
contraction (30).  Mechanistically, the actin cytoskeleton is attached to the cell membrane integrins 
and the integrins on the cell surface transmit the forces produced by the actin-myosin interaction 
to the attached substrate (31).  The cellular contractile forces are proposed to result from the 
traction due to the cell migration and/or the contraction of the cells.  As discussed in the Tissue 
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Wound Healing section, cells migrate into the injured site (4).  The propulsion of the cell through 
the matrix is a result of traction forces exerted on the matrix by the cells (32,33).  The other source 
of cellular force results from sedentary cells that contract, essentially pulling the matrix in 
toward the cell (34).  Therefore, forces on the matrix could be a result of a combination of cellular 
traction and contraction forces.  The studies in this thesis will not distinguish between these two 
cellular forces; instead, the resultant force of the matrix-cell complex due to the combination of 
these two forces will be studied. 
 
 Most studies on cellular contraction have predominantly focused on skin fibroblasts 
(12,35,36,37).  Interestingly, fetal skin fibroblasts were found to be less contractile than adult skin 
fibroblasts in vitro (12).  As adult and fetal skin have markedly different healing propensities (11,26), 
it suggests that fibroblast contraction may contribute to the different healing responses, 
specifically the formation of scar tissue.  In addition to the studies on skin fibroblast contraction, 
several studies found that calf patellar and rabbit flexor tendon fibroblasts were able to deform 
fibroblast populated collagen gels (FPCGs) (15,16,38) and that endotenon and synovial fibroblasts 
exhibit slightly different contractile forces (15,38).  As measure inf a force monitor system, tendon 
fibroblasts apparently have a different contraction pattern and a significantly lower maximum 
contraction force over 24h compared to skin fibroblasts (14).  Further, tendon fibroblast 
contraction can be inhibited by addition of 5-Fluorouracil (38), an antimetabolite, which indicates 
the ability to regulate tendon fibroblast contraction with exogenous cytokines.  These studies on 
fibroblast contraction provide a basis for investigating fibroblast contractility; however, 
additional studies are needed to further the understanding of human fibroblast contractility and 
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the differential effects of TGF-β1 and TGF-β3 on human fibroblast contraction and collagen 
synthesis. 
 
 During tissue wound healing, the ability of cells to contract is important for wound 
closure (26,39).  However, excessive cellular contraction can result in formation of scar tissue (12,26).  
Likewise, if cellular contraction is inhibited, wound healing may be impaired (12,26).  Thus, cellular 
contraction during wound healing must be in an optimal range to facilitate wound closure and 
also reduce scar tissue formation.   
 
 
 
2.4  In Vitro Models to Study Cellular Contractility 
 
 
 
 Under normal culture conditions, cells plated on polystyrene culture dishes, cellular 
contractility can not be studied because the substrate that the cells are attached to is too stiff.  
Since commonly used cell culturing techniques do not allow for visualization or quantification of 
cellular contraction, in vitro models have been developed to study cellular contractility, including 
the thin silicone membrane (TSM) (13,40) and cell populated collagen gel (CPCG) (12,18,41,42).   
 
 A creative solution to the limitation of traditional culture methods was the fabrication of a 
TSM to which the cells can attach and deform (13,40).  One challenge of this technique is that the 
membrane must be of very low stiffness so that the small forces produced by the cells can 
deform the underlying membrane.  Fabrication of a TSM is difficult, and the process is further 
complicated by the need to plate the cells onto the membrane without damaging it.  One study 
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using this model calculated the forces produced by cells during cellular division by measuring 
the number and length of the wrinkles produced under the cell body (13).  Although this model is 
capable of demonstrating cellular contractility, several limitations exist.  First, the cells are plated 
on a two-dimensional surface, whereas cells in vivo are in a three-dimensional matrix.  In 
addition, the cellular forces can only be qualitatively demonstrated or indirectly estimated based 
on the extent of wrinkle formation under the cells.   
 
 The second model used to study cellular contractility is the CPCG (12,15,16,18,35,37,41,43).  In this 
model, cells are mixed with a collagen solution and poured into a predefined well.  After gel 
polymerization, the cells are embedded in the collagen gel.  To measure the amount of cellular 
contraction, the area or diameter of the gel is measured.  Therefore, a smaller collagen gel area 
corresponds to a larger cellular contraction force.  Further, the rate of contraction is inversely 
related to collagen concentration and directly dependent on the cell number (36,41,43).   
 
 Although measuring the CPCG area can be an efficient and effective means for 
monitoring cellular contraction, the contraction force is not being measured, i.e. the model is a 
semi-quantitative measurement of cellular contraction.  Further, the stiffness of the gel should 
increase as the gel area becomes smaller, therefore preventing small changes in cellular 
contraction from being detected.  This potentially makes the CPCG model insensitive to 
distinguish between certain treatments, such as various dosages of a growth factor treatment.  
Therefore, the CPCG can be a good model for determining if cells are contractile; however, the 
CPCG model may not be sufficient to quantify and determine small differences between 
treatments. 
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 To overcome the shortcomings of the TSM and CPCG models, several cell force monitor 
systems have been developed.  The main advantage of these systems is that they can quantify the 
force of contraction CPCGs (29,36,37,43).  For example, the system developed by Delvoye et al. used 
strain gages to measure forces produced by the FPCGs (36).  The fibroblasts in this system align to 
the long axis of the FPCG and the force produced by the FPCG is proportional to the number of 
cells and inversely proportional to the collagen density (36).  In another system, an isometric force 
transducer was used to measure the FPCG contractile force (29).  The culture force monitor (CFM) 
system (14,37,43) is a more recent system that quantifies the contractility of CPCGs and can detect 
different contractile patterns of different cell types (14).   
 
 Thus, these CFM systems offer the advantages of quantifying the CPCG contraction and 
are sensitive enough to determine differences in contraction due to different cell types.  In 
addition, the cells in these systems are in a three-dimensional collagen matrix under tension, 
which mimics the cells in vivo environment more closely.  These systems, however, also have 
several limitations.  Each device can only measure one sample at a time and the conventional 
strain gages used may not be sensitive enough to detect differences in cellular contraction forces 
due to minor variations in treatments.  Therefore, a more sensitive system that can 
simultaneously measure forces of multiple CPCGs, while maintaining the three-dimensional 
matrix is highly desired. 
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2.5  Cellular Contraction versus Collagen Synthesis 
 
 
 
 Cellular contraction, being an important component of wound healing, potentially affects 
other cellular responses necessary for wound healing.  During wound repair, the fibroblasts that 
migrate into the injured site must synthesize collagen to repair the extracellular matrix.  
Fibroblasts in collagen gels during short term culture (4 days) were found to secrete procollagen 
into the medium, while during long term culture (4 weeks), the cells synthesized α type I 
collagen that was incorporated into the matrix (44).  Therefore, the FPCG model can potentially be 
used to study cellular contraction and collagen synthesis simultaneously.  In support of cellular 
contraction affecting collagen synthesis, the actin cytoskeleton is thought to transduce signals for 
collagen and procollagenase synthesis, proteins involved in tissue remodeling (45).  Further, in a 
separate study, disruption of the actin cytoskeleton with cytochalasin D activated procollagenase 
IV (46).  Since cellular contraction requires the actin cytoskeleton (29), this suggests that cellular 
contraction may affect other cellular responses, such as collagen metabolism, which are 
important for wound healing.  Therefore, these findings support the projects working hypothesis 
that regulating cellular contraction may result in a corresponding regulation of other cellular 
responses, i.e. collagen metabolism, which are important for wound healing. 
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3.0  SPECIFIC AIMS OF THE THESIS 
 
 
 
During healing, many types of tissues form scar tissue, which is characterized by an 
altered biochemical composition, distorted tissue architecture, and decreased mechanical 
properties (5,6,7,17).  As a result of these altered tissue characteristics, scar tissue can impair the 
normal function of the tissue.  For example, transection of rabbit flexor tendons resulted in 
formation of scar tissue, which significantly decreased the range of motion compared to those 
not injured (19).  Regarding the formation of scar tissue, excessive cellular contraction is known to 
be a contributor (26);  therefore, it is necessary to regulate this cellular response in order to reduce 
the formation of scar tissue.  Recent studies have begun to untangle the intricate mechanisms of 
wound healing; however, there remains only limited knowledge about the role of cellular 
contraction during wound healing, particularly in tendons and ligaments.  TGF-β1 and TGF-β3, 
two growth factors predominant in adult tissue healing (47), were both found to increase human 
skin fibroblast contraction and collagen synthesis (18).  However, TGF-β3 reduced the formation 
of scar tissue in rat skin wounds compared with TGF-β1 and non-treated controls (17).  It remains 
to be determined, nevertheless, whether TGF-β1 and TGF-β3 differentially regulate cellular 
contraction.  Therefore, the overall objective of this project is to reduce the formation of scar 
tissue during healing by regulating cellular contraction.  Toward this overall objective, the 
specific aims of this thesis are to examine human fibroblast contractility in vitro and determine 
the differential effects of TGF-β1 and TGF-β3 on human fibroblast contraction and collagen 
synthesis, important cellular functions in tissue wound healing. 
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3.1  Specific Aim 1 
 
 
 
To determine whether human tendon fibroblasts are contractile using two in vitro models, 
the thin silicone membrane (TSM) and fibroblast populated collagen gel (FPCG).  On one hand, 
cellular contraction is known to be necessary for wound closure (26).  On the other hand, however, 
excessive cellular contraction contributes to the formation of scar tissue (12,26).  If tendon 
fibroblasts are contractile, then regulating the cells contraction may reduce the formation of scar 
tissue in tendons.   
 
Hypothesis 1:  We hypothesize that human patellar tendon fibroblasts are also 
contractile, since calf patellar tendon and rabbit flexor tendon fibroblasts have been found 
to contract collagen gels (14,15,16,38). 
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3.2  Specific Aim 2 
 
 
 
To develop a multi-station culture force monitor (CFM) system to characterize 
contraction of human fibroblasts in a collagen gel, and use this system to determine whether 
human tendon and skin fibroblasts exhibit different contraction patterns.  Current force monitor 
systems can quantify FPCG contraction (29,36,37,43); however, they are limited to testing one sample 
per device and often require a large number of cells per gel.  Using one of these systems, 
fibroblasts from rabbit flexor tendons were found to contract significantly less than human skin 
fibroblasts (14).  The contractility of human tendon fibroblasts, however, has yet to be quantified 
and compared with human skin fibroblasts.  Different contractile characteristics of cells may 
provide a basis for the differential healing responses of tissues and indicate the need for tissue 
specific methods to regulate cellular contraction in order to reduce the formation of scar tissue. 
 
Hypothesis 2:  Rabbit flexor tendon fibroblasts were shown to contract significantly less 
and with a substantially different contraction pattern from human skin fibroblasts (14).  
Therefore, we hypothesize that human tendon fibroblasts contract a collagen gel to a 
lower degree and with a different contraction pattern compared with human skin 
fibroblasts. 
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3.3  Specific Aim 3 
 
 
 
To determine whether TGF-β1 and TGF-β3 differentially alter human fibroblast 
contraction and collagen synthesis.  It is known that during formation of scar tissue, both cellular 
contraction and collagen synthesis are over-stimulated (17,26).  Although both TGF- β1 and TGF-
β3 were found to increase human skin fibroblast contraction and collagen synthesis, only TGF-
β3 was found to reduce the formation of scar tissue in rat skin wounds (17).  Thus, if TGF-β1 and 
TGF-β3 differentially regulate cellular contraction and collagen synthesis of human fibroblasts, 
these growth factors may be used to regulate these cellular responses to reduce the formation of 
scar tissue.   
 
Hypothesis 3:  Since TGF-β1 and TGF-β3 elicit different healing responses in rat skin 
wounds (17), these two isoforms of TGF-β may induce differential effects on the 
fibroblasts in vivo.  In order to further understand the actions of these isoforms on human 
fibroblasts, we tested the hypothesis that treatment with either TGF-β1 or TGF-β3 
increases human fibroblast contraction and collagen synthesis in a dose dependent 
manner compared to non-treated controls.  Further, since TGF-β3 reduces the formation 
of scar tissue, we hypothesize that TGF-β3 increases human fibroblast contraction and 
collagen synthesis to a lower degree than TGF-β1. 
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In this thesis, the contractility of human fibroblasts was characterized and the effect of 
TGF-β1 and TGF-β3 on human fibroblast contraction and collagen synthesis will be determined.  
The quantitative data obtained from the multi-station CFM system will help to correlate cellular 
contraction with collagen synthesis, an important cellular response during wound healing.  The 
studies in this thesis also contribute to the understanding of the cellular and molecular 
mechanisms of tissue wound healing.  In addition, by understanding the contraction pattern of 
cells from a specific tissue, treatments can be tailored to properly regulate the cells contraction 
and reduce the formation of scar tissue during healing.   
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4.0  HUMAN FIBROBLAST CONTRACTION:  AN IN VITRO STUDY USING THE TSM 
AND FPCG MODELS 
 
 
 
4.1  Abstract 
 
 
 
Cellular contraction is necessary for wound closure; however, excessive contraction may 
lead to the formation of scar tissue.  After injury, tendons can heal with scar tissue, characterized 
by a disorganized collagen matrix and lower mechanical properties compared to normal tendons.  
Few studies have examined at tendon fibroblast contraction and the role that it may play in 
tendon healing.  Therefore, the objective of this study was to determine whether human tendon 
fibroblasts contract in vitro, using the established TSM and FPCG models.  Human patellar 
tendon fibroblasts (HPTFs) were used in this study and found to significantly deform the TSMs 
and FPCGs, demonstrating that these cells are contractile.  Further, the cells contraction was 
dependent on the serum concentration, suggesting that the HPTF contraction can be regulated by 
environmental factors, such as growth factors.  In order to reduce formation of scar tissue, it is 
important to be able to regulate the cells contraction.  Since cellular contraction is a necessary 
component of skin healing, these findings suggest that contraction of human tendon fibroblasts 
may play a role in tendon healing.  Thus, additional studies are needed to further characterize 
human tendon fibroblast contraction and the role that it may play in tendon healing. 
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4.2  Introduction 
 
 
 
 Cellular contraction, defined as the force cells exert on the extracellular matrix, plays an 
important role in tissue wound healing (26).  However, since the cellular forces are very small (~ 1 
nN/cell) (29,36,37,43), these forces can not be easily demonstrated, let alone quantified using normal 
culture techniques, i.e. culturing cells on polystyrene culture dishes.  An innovative solution to 
the inability to visualize cellular contraction was developed by Harris et al. (40).  Harris and 
coworkers fabricated a thin silicone membrane (TSM), about 1 µm thick (40).  Using this TSM, 
cells were cultured and observed with light microscopy.  Remarkably, fibroblasts, parenchyma 
cells, macrophages, and other cells types visibly deformed the TSM, such that wrinkles formed 
underneath the cell bodies.  In a later study using ultraviolet irradiation to fabricate the TSMs 
consistently, the cellular forces were estimated by measuring the amount of force needed to 
create the wrinkles seen under the cells (13).  They used calibrated microneedles to push the 
cells, thereby correlating the amount of force with the number and length of wrinkles.  Thus, 
when the cell formed wrinkles in the membrane, they could estimate the amount of force the cell 
was exerting on the membrane (13).   
 
Another in vitro model to study cellular contraction was developed that used a three 
dimensional collagen gel (41).  In this model, a fibroblast populated collagen gel (FPCG) was 
formed by the polymerization of a cell-collagen mixture, thereby entrapping the cells in the 
collagen gel.  The area of the FPCG was found to decrease over time.  Since cell-free collagen 
gels did not deform, the deformation was cell-mediated and the cellular contraction could be 
semi-quantified by measuring the change in FPCG area.  Furthermore, this study demonstrated 
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that the FPCG contraction is inversely dependent on the concentration of collagen and directly 
dependent on the number of cells (41).  In other words, the more collagen, the stiffer the matrix 
will be, and the less it will be able to deform.  In addition, more cells can generate a larger force, 
thereby causing greater gel deformation.   
 
Both TSM and FPCG models provide a means to study cellular contraction, but each has 
its advantages and limitations.  The unique advantage of the TSM model is that it allows for 
visualization and estimation of the forces from a single cell.  However, cells are normally in a 
three-dimensional collagen matrix, such that the FPCG model offers the advantage of a cell 
being in an environment similar to in vivo.  Therefore, potential limitations of the TSM model 
are that it only allows for visualization of a few cells, the cells are on a two-dimensional 
substrate, and this model is technically demanding, i.e. it is difficult to fabricate usable 
membranes and quantify the cellular forces.  The major limitations of the FPCG model include 
its semi-quantitative measurement of cellular contraction, the inability to quantify the cellular 
forces of individual cells, and the increase in gel stiffness as a result of the smaller gel area.  
Overall, however, the FPCG model is advantageous as it provides for a simple, yet effective way 
to study cellular contraction, as well as simulating the in vivo cellular environment.   
 
As there is a great interest in reducing scar tissue formation in dermal wounds, many 
studies have investigated skin fibroblast contraction (2,12,18,35,48,49,50,51,52,53,54,55,56).  However, only a few 
studies have investigated tendon fibroblast contractility in collagen gels (14,15,16,38).  Although these 
studies suggest that tendon fibroblasts contract in vitro, cellular contractility is highly dependent 
on the species and type of cells (14).  These previous studies used calf patellar tendon (16) and rabbit 
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flexor tendon (14,15,38) fibroblasts; however, studies are needed to determine whether human tendon 
fibroblasts are also contractile.  Therefore, the objective of this study is to test the hypothesis that 
human tendon fibroblasts contract in vitro, using the TSM and FPCG models.  Since tendons 
also heal with scar tissue (5,7,57), understanding human tendon fibroblast contraction may help to 
reduce the formation of scar tissue in healing tendons.   
 
 
 
4.3  Materials and Methods 
 
 
 
HPTFs were obtained from pieces of patellar tendon autografts of healthy donors 
undergoing anterior cruciate ligament reconstruction.  The protocol for obtaining the tendon 
samples was approved by the Institutional Review Board of the University of Pittsburgh Medical 
Center (Assurance of compliance # IORG0000196).  In a laminar flow hood, the tendon samples 
were washed twice with phosphate-buffered saline (PBS; Invitrogen, CA) and minced in a 100 
mm culture dish.  The tendon samples were maintained in DMEM supplemented with 10% fetal 
bovine serum (FBS; Invitrogen) and 1% penicillin/streptomycin (P/S; Invitrogen) in 5% CO2 at 
37oC and 100% humidity.  After the HPTFs grew out of the sample and became confluent, the 
cells were sub-cultured 5 to 7 passages to obtain a sufficient number of cells for experiments. 
 
 The protocol for the TSMs was adapted from that described by Harris et al. (40).  Briefly, 
glass microscope coverslips were covered with liquid silicone (RTV ME 601A; Wacker 
Silicones Corporation, MI).  The coated coverslips were inverted and slowly passed over a 1 inch 
Bunsen burner flame for about 1 second, just long enough to see the surface of the silicone fluid 
polymerize.  The TSMs were then set into a 35 mm tissue culture dish (Falcon) and covered with 
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a Pronectin-F solution (10 µg/mL) to promote cell attachment.  The Pronectin-F solution was 
washed one time with PBS.  To prepare the cells for plating, the HPTFs were trypsinized, 
centrifuged, and then diluted to various cell densities.  The cell solution was pipetted onto the 
TSM.  After 30 minutes of incubation, additional medium was added to cover the TSM.  Cells on 
the TSM were incubated overnight to allow attachment and spreading.  Microphotographs were 
taken using a Nikon inverted microscope (TE200) and camera (Nikon, FX-35DX) for 
documentation of the wrinkles.  In a separate experiment to demonstrate that the TSM wrinkles 
were cell mediated, HSFs were plated on the TSM.  The medium was aspirated and replaced 
with trypsin to cause the cells to detach from the membrane.  Microphotographs were taken at 
30s, 30m, 1h, and 2h for documentation  
 
For the FPCGs, a solution of ~98% bovine collagen type I (Cohesion Technologies Inc., 
CA) was mixed with 0.1 M NaOH and 10X PBS (ratio of 8:1:1).  FPCGs were prepared in wells 
of an untreated 12 well plate (Fisher, PA) by mixing 0.5 mL of the collagen gel solution (2.56 
mg/mL) and 150,000 HPTFs in 0.3 mL of AIM-V (Invitrogen), a serum-free medium.  After gel 
polymerization, 1.5 mL of DMEM with 10% FBS and 1% P/S was added to each FPCG.  For 
determining serum dependence, 1.5 mL of DMEM with 0% FBS, 1% FBS, or 10% FBS were 
added to the corresponding FPCGs.  Digital photographs of the gels were taken at 4 time points 
(12, 24, 36, and 48h) with a Kodak DC3400 camera, and the digital images were analyzed using 
Scion Image Software (Scion Corporation, Frederick, MD).  Gel areas were normalized by the 
initial area of the gel, i.e. the area of the well (3.8 cm2).  Unpaired t-test was used for data 
analysis, with a significance level set at α = 0.05. 
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4.4  Results 
 
 
 
 HPTFs readily attached and spread on the TSM (Figure 1), so that wrinkles (white 
arrow) formed directly underneath the cells (black arrow), predominantly perpendicular to the 
long axis of the cell.  Further, higher densities of HPTFs resulted in larger numbers of wrinkles 
throughout the membrane, and localized cells appeared to align in a similar direction and form 
wrinkles perpendicular to their alignment (Figure 2).  To demonstrate that the wrinkles on the 
TSM were cell-mediated, HSFs were plated on a TSM and allowed to attach for several hours.  
After a 30s incubation with trypsin, the HSFs detached from the TSM (Figure 3A).  The 
wrinkles gradually decreased and nearly disappeared after 2 hours (Figure 3D).  Note that 
fabrication of the TSMs causes wrinkles (black arrow, Figure 3A) that are clearly 
distinguishable from the wrinkles produced by the cells (white arrow, Figure 3). 
 
Figure 1  HPTFs are contractile, 
which is demonstrated by the 
formation of  wrinkles (white 
arrow) underneath the cells (black 
arrow) plated on a TSM. 
Figure 2  HPTFs at a high density 
substantially wrinkle (white arrow) the 
underlying TSM.  Local populations of cells 
align in a similar direction with the wrinkles 
forming perpendicular to preferred cell 
direction. 
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 For the FPCG model, the HPTFs were embedded in the collagen gel.  Collagen gels 
without cells underwent no change in area, so the gel remained the size of the well (Figure 4A).  
After a period of 24 hours, the FPCG areas decreased significantly (Figure 4B) from the initial 
area, the area of the well.  Moreover, the HPTFs responded differently depending on the 
concentration of FBS (Figure 5).  The FPCGs in 10% FBS had a significantly smaller gel area 
compared with those in 1% FBS.  The HPTFs in 0% FBS were rounded in shape and not well 
integrated into the collagen gel, with no detectable change in gel area. 
 
 
 
 
 
Figure 3  The wrinkles (white arrow) in the TSM are cell-mediated.  Addition 
of trypsin caused the cells to detach from TSM after 30 s (A).  The wrinkles 
disappear after 2h following cell detachment (D).  Also notice that wrinkles 
formed during TSM fabrication (black arrow) are distinguishable from wrinkles 
produced by cells. 
A)  30 sec B)  30 min 
C)  1 hr D)  2 hr 
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Figure 4  HPTFs contract a three-dimensional collagen gel.  
The area of a cell free collagen gel remains unchanged (A).  
HPTFs in collagen gel significantly deform the gel to about 
25% of its original area, i.e. the area of the well, after 48h in 
10% FBS (B). 
Figure 5  FPCG contraction increased with increasing serum concentration. 
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4.5  Discussion 
 
 
 
In this study, HPTFs were found to deform both TSMs and collagen gels, indicating that 
these human tendon fibroblasts are contractile.  In addition, the FPCG contraction was found to 
be dependent on serum concentration.  Since cellular contractility is necessary for wound closure 
(26), these findings suggest that tendon fibroblast contractility can be further studied to understand 
its role in tendon healing.  The finding that HPTF contraction depends on the concentration of 
FBS demonstrates the ability of biological factors to regulate HPTF contraction. 
 
 Although both the TSM and FPCG models were used to demonstrate HPTF contraction, 
the magnitude of the contraction force has yet to be determined.  Further, a method to 
consistently plate the cells on the TSM without damaging the membrane proved to be difficult.  
Often, the membrane would break and the liquid silicone underneath the membrane would leak 
out, thereby increasing the friction between the TSM and coverslip.  Thus, the cellular forces 
were not able to overcome the frictional force, therefore preventing the formation of the 
wrinkles.  The FPCG model, although a semi-quantitative way to measure cellular contraction, 
was considerably easier to use than the TSM and appears to be a useful method for investigating 
cellular contraction.  An apparent limitation of the FPCG model is that as the collagen gel 
contracts, the gel should become denser, therefore increasing its stiffness.  This may limit the 
sensitivity of the model because as the gel increases in stiffness, a larger force is needed to 
deform the gel.  Therefore, treatments causing only small changes in cellular contraction may not 
be distinguishable because the differences in cellular forces may not cause detectable changes in 
gel areas. 
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This study demonstrates that human tendon fibroblasts are contractile.  The TSM model 
qualitatively demonstrated HPTF contraction, whereas the FPCG model semi-quantitatively 
measured the cells contraction.  Addressing the shortcomings of the FPCG model, several force 
system have been developed (29,36,37,43).  With further studies on tendon fibroblast contraction, 
means to regulate the cells contraction may be investigated to potentially reduce the formation 
of scar tissue in healing tendons.  For future studies, a force system will be developed to monitor 
contraction of multiple FPCGs simultaneously, allowing human fibroblast contractility to be 
quantified for comparison between cells from different tissues and cells exposed to growth 
factors, i.e. TGF-β1 and TGF-β3.   
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5.0  DEVELOPMENT OF A MULTI-STATION CULTURE FORCE MONITOR 
SYSTEM 
 
 
 
5.1  Abstract 
 
 
 
 Cellular contraction contributes to the formation of scar tissue.  To study the contractility 
of cells in vitro and its potential contribution to scar tissue formation, a multi-station culture 
force monitor (CFM) system has been developed.  This system consists of four vertical 
cantilever beams with semiconductor strain gages and a computerized data acquisition unit to 
monitor contractile forces of the cells in a collagen gel.  Calibration showed that this system has 
a highly linear voltage-force relationship (R2 > 0.99).  Using this system, we tested the 
hypothesis that human patellar tendon fibroblasts (HPTFs) and human skin fibroblasts (HSFs) 
exhibit different contraction patterns and maximum contraction force.  The HPTFs (0.1 nN/cell) 
were found to contract with about half of the maximum contraction force produced by the HSFs 
(0.2 nN/cell).  These findings are consistent with the range found in literature.  The unique 
features of this system are the use of semi-conductor strain gages to increase sensitivity and the 
ability to simultaneously test multiple samples.  Further, using this system, fibroblasts from 
different tissues were differentiated based on their contractile patterns, suggesting that treatments 
to regulate cellular contraction need to be tailored to the specific tissue.  Future studies will 
investigate treatments that have the potential to regulate cellular contraction and reduce the 
formation of scar tissue. 
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5.2  Introduction 
 
 
 
Thus far, human skin and tendon fibroblasts were shown to be contractile using the thin 
silicone membrane (TSM) and cell populated collagen gel (CPCG) models (Chapter 4).  
However, both of these models have certain limitations for studying cellular contractility.  The 
TSM uses a two-dimensional membrane, is primarily qualitative, and is difficult to use for 
experiments.  The CPCG model has several advantages compared with the TSM model; it is a 
three-dimensional matrix similar to in vivo and it is relatively simple to use.  However, the main 
limitations of the CPCG model are that it may be insensitive to slight differences in experimental 
conditions and it is semi-quantitative.  Therefore, it is highly desired to use a system that can 
quantify cellular contraction forces.  Several force systems have been developed to address these 
limitations (29,36,37,43).  Systems using strain gages were developed to measure forces of FPCGs 
(36,37).  They showed that the fibroblasts in this system align to the long axis of the FPCG and skin 
fibroblasts produced 0.1 to 1 nN/cell (36,37).  Further, the cell-mediated contraction force was 
found to be proportional to the number of cells and inversely proportional to the collagen density 
(36).  Another system used an isometric force transducer to measure the FPCG contractile force (29) 
and found human skin fibroblasts to produce about 0.6 nN/cell on average.  These studies clearly 
illustrate the difficulty in measuring cellular contraction, as the contraction force is on the order 
of 1 nN/cell.  Therefore, many of these systems use 5 to 10 million cells per collagen gel so the 
resultant force is large enough to detect. 
 
The most recent force system used to measure cellular contraction is the culture force 
monitor (CFM).  It can measure FPCG contraction like the other systems, but with better 
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resolution, and therefore it only needs to use 2 to 5 million cells per gel (37,43).  For the CFM, the 
CPCG is formed in a silicone well with two porous polymer bars on the sides or ends of the well, 
such that when the gel polymerizes, it is attached to the polymer bars.  A wire frame extends 
from the polymer bars, such that one end of the gel is connected to a cantilever beam with strain 
gages attached at its base, while the other end is held fixed.  Thus, the force produced by the 
CPCG is transferred via the wire frame to the beam, causing the beam to bend.  The strain gages 
at the base of the beam monitor the resultant strain due to beam bending.  By calibrating the 
beam with known weights, the force produced by the CPCG can be calculated directly from the 
voltage recorded by the strain gages.   
 
These systems are quite sensitive, measuring CPCG contraction in the range of 1200 
dynes (1 dyne = 10-5 N) for about 10 million cells, corresponding to about 1.2 nN/cell (43).  
Because of the need to compare the effect of biological factors (e.g., growth factors) that play an 
important role in wound healing, as well as study the effect of cellular contraction on collagen 
synthesis, a multi-station culture force monitor (CFM) system has been developed.  This multi-
station CFM system facilitates statistical design and analysis of experiments to study cellular 
contractilityby testing four samples simultaneously under similar environment conditions.  Thus, 
this chapter presents the design and development of this new multi-station CFM system.  Human 
skin fibroblasts were chosen to demonstrate the feasibility of this system as they are easy to 
culture, abundant, and their contractile forces are well documented in literature (14,29,36,37,43).  
Further, the contractile patterns and maximum contraction force of HSFs and HPTFs in a 
collagen gel will be compared using the data obtained from this new CFM system.   
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5.3  Materials and Methods 
 
 
 
5.3.1  CFM System 
The new multi-station CFM system consists of the CFM apparatus (Figure 6A) and a 
computerized data acquisition unit, capable of simultaneously monitoring contractile forces of 
multiple CPCGs.  The base of the CFM apparatus is an aluminum platform that can 
accommodate up to six circuits, each capable of monitoring CPCG contraction.  The support rod 
assembly mounted to the base of the CFM provides a framework for positioning and fixing the 
beam-clamps (Figure 6B).  Further, the fixation units opposing the support rod assembly allow 
one end of the gel to be fixed, as well as providing a means for adjusting gel tension.  The beam 
clamps, made of stainless steel, rigidly fix the beams and can move along the support rod 
assembly for proper positioning during experiments.   
 
 
Figure 6  The CFM apparatus in the incubator (A) is connected to an external 
computerized data acquisition unit that displays and records the voltages from the semi-
conductor strain gages.  The force generated by the CPCG is transmitted to the beam via 
the wire frames, while the bending of the beam is monitored by the semiconductor strain 
gages mounted at the base of the beam, near the beam clamp (B).   
B A 
Wire Frames
Vyon Bars
FPCG
Semiconductor Strain Gages
Beam
Beam clamp
Fixation 
Unit
Force
Silicone Dish
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The beams, which detect the cellular contractile forces, are made of aluminum (95.2 x 5.0 
x 0.25 mm; Youngs modulus, E = 70 GPa), permitting sufficient beam strain under the expected 
CPCG forces in our CFM system (~ 200 dynes).  A small suture loop (braided polyester suture, 
4-0; Ethicon, NJ) tied to the beam through a 0.4 mm hole located 76.2 mm from the clamp 
connects the gel attachment unit to the beam.  To measure beam strain, two semiconductor strain 
gages were mounted on each side of the beam (gage factor = 140; resistance ~ 400Ω; Micron 
Instruments, CA) in a full Wheatstone bridge configuration, located 1.6 mm from the clamp.  In 
addition, a power supply (Hewlett Packard 6237B Power Supply) provides 4V DC excitation 
voltage to all the semiconductor strain gages.   
 
The silicone dishes (70 x 30 x 10 mm) that contain the CPCGs, are custom made using a 
molding process as described previously (58).  Briefly, two silicone components (RTV ME 601A 
and 601B; Wacker Silicones Corporation, MI) are mixed in a ratio of 10:1.  After being 
degassed, the silicone mixture is poured into a multiple-dish mold made of acrylic (Plexiglass).  
The silicone dishes obtained from this molding process are hydrophobic, thereby minimizing the 
attachment of cells and the collagen gel to the dish.  Each silicone dish contains three separate 
wells, and the dish height was decreased to accommodate the connection of the CPCGs to the 
beams and fixation units. 
 
The force generated by the cells is transmitted from the CPCG to the beam via the gel 
attachment unit (Figure 6B).  The gel attachment unit (Figure 7) is composed of two parts, a 
porous vyon bar and a wire frame.  The CPCGs polymerize into the porous vyon bars (23 x 8 x 3 
mm; Porvair Inc., NC) located at the ends of the silicone dish.  The wire frames (0.36 mm 
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stainless steel wire) extend vertically from the vyon bars to allow easy attachment to the beam 
and tension unit.  As one end of the gel is fixed by the tension unit, the contraction of the CPCG 
is transmitted to the beam by the gel attachment unit and suture, causing the beam to deflect, 
which is monitored by the semiconductor strain gages (Figure 6B).   
 
 The data acquisition unit that receives the signal voltage is composed of a data 
acquisition (DAQ) card (6024E; National Instruments, TX), shielded connector block and cable 
(National Instruments, TX), and a personal computer.  A Labview 5.1 program was developed to 
display and record the output voltage signals from the semiconductor strain gages (see 
description in Appendix).  The Labview program can record signals at various time points and 
variable sampling rates.  For experiments in this study, the voltage signals were recorded for 10 
seconds at 10 Hz, every 10 minutes.  Each data point corresponds to the mean of the respective 
100 samples.   
 
 
 
 
 
Figure 7  Schematic of the gel attachment unit composed of 
the vyon bar (A) to which the FPCG attaches, and the wire 
frame (B) that transmits the force to the beam or fixation 
unit. 
40 mm 
10 mm 
3 mm 
8 mm 
23 mm 
A 
B 
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5.3.2  Calibration 
Calibration was performed for each individual circuit, i.e., the components required to 
monitor each individual beam deflection (beam, strain gages, wire, connecting block, computer, 
and Labview program).  For calibration, the beams were set in a horizontal position, such that 
known weights could easily be suspended from the beam via the suture loops.  The force from 
the weight causes the beam to bend, and the resulting beam strain is detected by the strain gages.  
Force is related to strain as shown by the following equation: P = E*b*ε*h2/(6*L); P is a point 
force, E is Youngs modulus, b is the beam width, ε is the beam strain, h is the beam thickness, 
and L is the distance from the location of the point force to the location of the strain gages.  
Wires of different lengths were cut and weighed using an analytical balance (accuracy of about 
1.6 dynes; A-200D, Denver Instrument Company, CO).  The weights of six wire pieces were 20, 
39, 58, 77, 120, and 243 dynes, which covered the expected range of cellular contractile forces 
for about two million cells.  For each applied weight, 300 voltage outputs (10 Hz for 30s) were 
recorded and averaged to obtain one data point.  This calibration was repeated three times.  
Linear regression yielded the voltage-force relationship for each circuit.  Therefore, the 
calibration factor for each circuit, which is the slope from the linear regression of the voltage and 
force data, is used to calculate the force for a given voltage.  Note that the calibration was 
performed in the same environment as that for monitoring cellular contractile forces, in an 
incubator at 37oC, 5% CO2, and 100% humidity.  After about three months, the CFM system was 
recalibrated.  Although there was a change in the baseline voltages, the calibration factors 
remained similar to the previous calibration. 
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5.3.3  Experiments for Measuring Fibroblast Contraction    
HSFs and HPTFs were maintained in DMEM supplemented with 10% fetal bovine serum 
(FBS) and 1% penicillin/streptomycin (P/S; Invitrogen, CA) in 5% CO2 at 37oC and 100% 
humidity.  The cells were sub-cultured to obtain sufficient numbers of cells for each experiment 
(HSFs  passage < 20; HPTFs  passage < 8).  A collagen gel solution was made by mixing 
collagen stock solution (~98% bovine collagen type I; Cohesion Technologies Inc., CA), 0.1 M 
NaOH, and 10X PBS in a ratio of 8:1:1.  FPCGs were prepared in the rectangular silicone dishes 
by mixing 5 mL of the collagen gel solution (2.56 mg/mL) and 2x106 HSFs or HPTFs in 3 mL of 
medium.  The FPCG solution was pipetted into the silicone dish and around the porous vyon 
bars. The FPCGs were incubated for 10 minutes to initiate gel polymerization, which was 
followed by the addition of 7 mL of medium to each dish to allow FPCG to float in the medium.  
For all experiments in this study, DMEM supplemented with 10% FBS and 1% P/S was used.  
The FPCGs were attached to the multi-station CFM system and a pretension of 2 to 5 mV, or 4 to 
10 dynes, was applied to each FPCG.  The FPCG forces were monitored for about 20h.  Since 
HSFs reach a maximum level of contraction after about 8h and gradually decreasing after about 
13h, monitoring cellular contraction for 20h allows the rate of initial contraction and the 
maximum contraction force to be determined.  Voltage readings taken every 10 minutes at 10 Hz 
for 10 seconds were averaged to yield one data point, resulting in 6 data points/h.  To 
demonstrate that the FPCG forces were dependent on cell number, FPCGs were formed with 0, 
2, and 3 x 106 HSFs/gel and their contraction was monitored for 20h. 
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5.4  Results 
 
 
 
 A CFM system with four circuits was successfully developed to measure cellular 
contractile forces (Figure 6A).  The weight calibration of the system was effective and 
repeatable. With this method of calibration, it was shown that there was a highly linear voltage-
force relationship for all four circuits (R2 > 0.99) (Figure 8).  This linear relationship means that 
the voltage output from the semiconductor strain gages is proportional to the force bending the 
beam throughout the range of the forces tested (≤ 240 dynes).  Thus, the calibration factors, i.e., 
the slopes of the voltage-force lines from linear regression, for the four circuits were found to be  
Figure 8  Calibration curves for each of the 4 circuits, show the highly 
linear voltage-force relationships (R2 ≥ 0.99).  The initial voltage at 0 dynes 
represents the beams in the horizontal configuration.  Although each circuit 
has a different initial voltage since the Wheatstone bridges were not 
balanced, the voltages can be zeroed during post-processing of the data. 
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2.6, 2.6, 2.7, and 2.8 dynes/mV.  Repeated calibration after several months resulted in nearly the 
same calibration factors, with only a shift in the baseline voltage for each circuit.  Further, the 
accuracy of the CFM system on average was determined to be about 1 dyne. 
  
To demonstrate the feasibility of this CFM system, contractile forces of HSFs in a 
collagen gel were measured.  Visually, the cell-free collagen gel remained the same area of the 
silicone dish (Figure 9A), whereas the sides of the FPCG deformed into a parabolic shape 
(Figure 9B), indicating that the HSFs are contractile.  Further, force measurement with the CFM 
system showed that the cell-free collagen gels produced forces less than 10 dynes (Figure 10).  
In contrast, 2 x 106 HSFs in a collagen gel produced a maximum force of about 45 dynes, 
corresponding to ~ 0.2 nN/cell on average (Figure 10).  The contraction pattern of these HSFs 
can be divided into four different phases, phase I through phase IV.  The first phase begins after 
the FPCGs are attached to the CFM and ends at the time that  
Figure 9  A cell free collagen gel in a silicone dish well (30 x 90 mm) remains the 
size of the well, with no visible deformation (A).  A FPCG significantly deforms 
and pulls away from the sides of the dish (white arrow), with the sides of the gel 
becoming parabolic in shape (B). 
A 
B 
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the contraction curve reaches the minimum force value (0 to 2h).  During the second phase, 
which consists of the initial increase in contraction force (3 to 7h), the FPCG force rapidly 
increased to ~ 45 dynes, the maximum force produced by the FPCG.  During phase III, the force 
reaches an equilibrium force, followed by a slow decrease in force during the fourth phase.  
Notice that the similar contractile patterns of the two FPCGs (Figure 10) are due to the same 
experimental conditions applied.   
 
 Further, the HPTFs (2 million) in a collagen gel produced a significantly different 
contractile pattern (Figure 11) than HSFs (2 million; Figure 10).  The contraction force of the 
HPTFs increased throughout the experiment.  The contraction force reached a temporary 
equilibrium force from 5 to 10h, followed by a second and greater rise in force.  The force rate 
then decreased, approaching an apparent equilibrium level after 20h.  The maximum of about 20 
dynes for 2 million HPTFs was recorded at the end of the experiment (~ 36h), corresponding to 
0.1 nN/cell on average, which is half of the maximum force produced by the HSFs.  Notice 
again, the similar contractile patterns between these two FPCGs in this experiment under the 
same experimental conditions (Figure 11), indicating that the results from the different circuits 
are reliable and comparable.  In all experiments, cell viability was measured using an MTT assay 
to verify that the cells were viable.   
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Figure 10  Contraction of HSFs demonstrates the feasibility of the multi-station 
CFM system to monitor cellular contraction.  The cell-free collagen gels 
maintained a constant force throughout the experiment, whereas the contraction of 
2 million HSFs per collagen gel resulted in an average force of 0.2 nN/cell at 
about 13 hrs. 
Figure 11  HPTFs (2 million) in a collagen gel produce 20 dynes of maximum 
contraction force.  These tendon fibroblasts have a markedly different contractile 
pattern and a significantly lower maximum contraction force than HSFs (Figure 10). 
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5.5  Discussion 
 
 
 
In this study, a multi-station CFM system was successfully developed to investigate 
cellular contractility.  Calibration of the system demonstrated a highly linear relationship (R2 > 
0.99) between the voltage output and applied force.  The most significant advantage of this 
system, however, is its ability to test multiple samples simultaneously.  This feature facilitates 
statistical design and analysis of experiments to study the effects of growth factors, such as TGF-
β (18), on cellular contractility. 
 
To demonstrate the feasibility of this system in measuring cellular contraction, HSFs 
were used because they are readily available, easy to culture, and most importantly, their 
contractility is well documented (14,29,37,43).  Using this system, HSFs were found to produce 0.2 
nN/cell on average.  This result is consistent with previous studies using similar devices, which 
showed that skin fibroblasts in a collagen gel produce between 0.1 and 10 nN/cell (29,36,37,43).  
Similar to previous systems, this CFM system only measures contraction of a population of cells 
in a collagen matrix, not of the individual cells.  Therefore, the value of force/cell is a calculated 
average force that can only be considered as a rough estimate for comparison with previous 
studies.  The resultant contraction pattern (shape, contraction rate, initial contraction time) and 
the maximum FPCG force are better characteristics for comparison.   
 
Due to the nature of this system, setup of the FPCG, particularly the connection of the 
FPCG to the CFM system is necessary for obtaining data.  A potential problem with this system 
is that the FPCG can stick to the sides of the silicone dish, preventing force to be transferred to 
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the CFM system.  To minimize the occurrence of this problem, the vyon bars are placed a small 
distance from the end of the well to minimize their interaction with the silicone dish, and the 
silicone dishes are replaced as necessary, as the problem of FPCG attachment to the dish is more 
apparent in the older silicone dishes.  More noteworthy are the main advantages of this system 
over the previous force systems: 1. Because of the increases sensitivity due to the semiconductor 
strain gages, only 2 million cells/gel are needed to detect contractile forces for the fibroblasts 
tested; 2. Four FPCGs can be tested simultaneously in the same system, minimizing the 
variability due to time and environments; 3. The contraction patterns between the beams are 
surprisingly similar, allowing for comparison of contraction patterns between the beams.   
 
Using this multi-station CFM system, this study showed that contractile patterns and the 
maximum contraction force are strikingly similar under the same experimental conditions, 
indicating that this system is reliable and can be used to compare cellular contraction patterns 
under different treatments.  Further, this study demonstrated that HSFs have a significantly 
different contractile pattern and maximum contraction force compared to HPTFs, suggesting that 
this system can be used to differentiate between cells from different sources.  Thus, this new 
multi-station CFM system will be a useful tool to study the effects of biological factors (e.g. 
growth factors) on cellular contraction.  In addition, this system can be used to examine the 
effects of cellular contraction on collagen production, which is known to be involved in the 
formation of scar tissue. 
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6.0  THE DIFFERENTIAL EFFECTS OF TGF-b 1 AND TGF-b 3 ON HUMAN 
FIBROBLAST CONTRACTION AND COLLAGEN SYNTHESIS 
 
 
 
6.1  Abstract 
 
 
 
Transforming growth factor-b1 (TGF-b1) and TGF-b3, which play important roles in the 
maintenance and repair of tissues, were both found to increase cellular contraction in vitro, but 
only TGF-b3 was found to reduce the formation of scar tissue in vivo.  Since excessive cellular 
contraction can contribute to formation of scar tissue, an overproduced disorganized collagen 
matrix, we hypothesize that TGF-b3 increases human fibroblast contraction and collagen 
synthesis to a lesser degree than TGF-b1.  To test this hypothesis, the multi-station culture force 
monitor system was used to measure the contractility of FPCGs.  Both, the contraction pattern 
and collagen synthesis were found to be TGF-b1 and TGF-b3 dose dependent.  The 5 ng/mL 
dose of TGF-b1 or TGF-b3 resulted in the largest increase in maximum contraction force (360% 
and 180% of controls, respectively) and procollagen levels (750 and 600 ng/mL, respectively) 
compared to the other dosages (1 and 25 ng/mL).  Further, TGF-b3 induced less cellular 
contraction and collagen synthesis than TGF-b1 at each dosage.  Also, the preliminary data 
suggested that a strong correlation existed between the maximum contraction force and degree of 
collagen synthesis.  These findings suggest that TGF-b3 may induce a lesser degree of cellular 
contraction and collagen synthesis in healing tissues compared to TGF-b1. 
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6.2  Introduction 
 
 
 
 Growth factors are known to play an important role in the maintenance and repair of 
tissues.  Of interest in this study are two transforming growth factor-β (TGF-β) isoforms:  TGF-
β1 and TGF-β3.  As noted previously, unlike adult skin wounds, fetal skin wounds heal without 
scar formation (20,26).  Further, all the TGF-β isoforms were found to be up-regulated in adult 
wounds, but remained unchanged in fetal wounds (47), suggesting that these growth factors may 
contribute to the different healing responses in adult and fetal tissues.  More importantly, the 
higher level of TGF-β3 compared to that of TGF-β1 is important in regulating the healing 
process in fetal tissue and may contribute to the scar-free healing (59).  In an earlier study, these 
two TGF-β isoforms were found to have differential effects on the formation of scar tissue:  
TGF-β3 reduced the formation of scar tissue, whereas TGF-β1 induced the formation of scar 
tissue in rat skin wounds compared to the non-treated controls (17).  In another study, a 
neutralizing antibody to TGF-β1 increased postoperative range of motion at the proximal and 
distal interphalangeal joints after transection of the flexor tendon in rabbits (19), implying that 
TGF-β1 is involved in formation of scar tissue, and down-regulation of TGF-β1 levels can limit 
adhesion and scar formation, and thus improve tendon function.   
 
At the cellular level, TGF-β1 and TGF-β3 have both been found to regulate cellular 
processes important for tissue wound healing, namely increasing skin fibroblast contraction, 
proliferation, and collagen synthesis (12,18).  However, as a differential response is seen by the 
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application of either TGF-b1 or TGF-b3 to healing tissues, one would expect a corresponding 
differential response at the cellular level, i.e. cellular contraction and collagen synthesis. 
 
Cellular contraction, the force cells exert on the extracellular matrix, is a necessary 
component for wound contraction (26).  In spite of its necessity, excessive cellular contraction 
contributes to the formation of scar tissue (12,26).  A previous study has shown that TGF-b1 and 
TGF-b3 increase human skin fibroblast contraction (18).  However, since that study was unable to 
detect differences in cellular contraction from the TGF-b1 and TGF-b3 treatments, further 
studies are needed to determine if these growth factors induce differences in cellular contraction.  
Although most studies on cellular contraction investigate skin fibroblasts, recent studies found 
that tendon fibroblasts are also contractile (14,15,16), which may affect tendon healing.  As cells have 
inherently different contraction patterns and responses to growth factors, studies are also needed 
to determine if TGF-b1 and TGF-b3 have similar effects on fibroblasts from a different tissue, 
i.e. tendon.   
 
Therefore, the objective of this study was two-fold.  The first was to determine whether 
TGF-b1 and TGF-b3 increase contraction of fibroblasts derived from human tendon and skin in 
a dose dependent manner; and the second was to determine if TGF-b1 treatment increases human 
skin fibroblast contraction and collagen synthesis to a greater degree than TGF-b3.  For the first 
objective, HSFs and HPTFs were used.  For the second objective, HSFs were chosen because 
their contractility and the effects of TGF-ß1 and TGF-ß3 are well documented (14,18,29,37,43,60) 
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6.3  Materials and Methods 
 
 
 
6.3.1  Cell Culture 
Pieces of patellar tendon autografts were obtained from healthy donors undergoing 
anterior cruciate ligament reconstruction.  The protocol for obtaining the tendon samples was 
approved by the Institutional Review Board of the University of Pittsburgh Medical Center 
(Assurance of compliance # IORG0000196).  These tendon samples were used for explant 
cultures to obtain the human patellar tendon fibroblasts needed for the experiments.  Briefly, the 
tendon samples were washed twice with phosphate-buffered saline (PBS; Invitrogen, CA) and 
minced in a 100 mm petri dish in a laminar flow hood.  The HPTFs were maintained in DMEM 
supplemented with 10% fetal bovine serum (FBS; Invitrogen) and 1% penicillin/streptomycin 
(P/S; Invitrogen) and in an atmosphere of 5% CO2 at 37oC and 100% humidity.  The HPTFs 
were left to grow out of the tendon sample, with the medium replaced every 3 days.  To obtain 
sufficient numbers of cells for experiments, the cells were sub-cultured 5 to 7 passages.  HSFs 
(passage < 20) were also maintained in DMEM supplemented with 10% FBS and 1% P/S.   
 
6.3.2  Measuring Contraction of HPTFs with the FPCG Model 
For the FPCGs, a solution of ~98% bovine collagen type I (Cohesion Technologies Inc., 
CA) was mixed with 0.1 M NaOH and 10X PBS (ratio of 8:1:1).  Free-floating FPCGs were 
prepared in wells of an untreated 12 well plate (Fisher, PA) by mixing 0.5 mL of the collagen gel 
solution (2.56 mg/mL) and 150,000 HPTFs in 0.3 mL of AIM-V (Invitrogen), a serum free 
medium.  After gel polymerization, 1.5 mL of AIM-V medium containing TGF-β1 (1, 5, and 25 
ng/mL), TGF-β3 (1, 5, and 25 ng/mL), or no TGF-β for controls was added to each well.  
   
  45 
Dosages were chosen based on those used in literature (18).  For the experiment, each dosage was 
applied to three FPCGs.  Photographs of the gels were taken at 5 time points (4, 8, 12, 24, and 48 
h) with a digital camera (Kodak DC 3400).  The digital images were analyzed using Scion Image 
Software (Scion Corporation, Frederick, MD), and the resulting gel areas were normalized by the 
initial area of the gel, i.e. the area of the well (3.8 cm2).  Unpaired t-test was used for statistical 
analysis of the data, with a significance level set at α = 0.05. 
 
6.3.3  Measuring Contraction of HSFs with the CFM System 
FPCGs used in the CFM system (Chapter 5) were prepared in rectangular silicone dishes 
by mixing 5 mL of the collagen gel solution and 2x106 HPTF in 3 mL of AIM-V, a serum-free 
medium.  The FPCG solution was pipetted into the silicone dish and around the vyon bars.  The 
FPCGs were incubated for 10 minutes, followed by addition of 7 mL of AIM-V to each dish with 
the appropriate treatments.  For each experiment, four samples were tested simultaneously, e.g., 
1) FPCG without TGF-β; 2) FPCG with 1 ng/mL TGF-β; 3) FPCG with 5 ng/mL TGF-β, and 4) 
FPCG with 25 ng/mL TGF-β.  These dosages were based on those used with the free-floating 
FPCG model.  The FPCGs were attached to the multi-station CFM system and contraction was 
monitored for 48h.  For all experiments, voltage signals were recorded for 10 seconds at 10 Hz 
every 10 minutes.  Each data point corresponds to the mean of the 100 voltage samples recorded 
every 10 minutes. 
 
6.3.4  Measurement of Cell Viability 
To determine the viability of the human fibroblasts at the end of the experiment, an MTT 
assay was used (61).  Briefly, 200 µL (or 500 µL for CFM) of MTT solution (5 ng/mL) was added 
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to the medium of the FPCGs.  These were then incubated at 37oC and 5% CO2 for 3h.  The 
supernatant was aspirated, and 2 mL (or 4 mL for CFM) of extraction buffer (15 mL DMF, 14.1 
ml H2O, and 6 g SDS) was added to each dish.  After overnight incubation at 37oC, the solution 
was diluted 1:5 with DI H2O and mixed thoroughly.  Duplicate samples of 200 µL were 
aliquotted into a 96-well plate, and the absorbance, or optical density (OD) value, was measured 
using a microplate reader (Spectra MAX 190, Molecular Devices, CA) at 550 nm.  The resultant 
OD value represents the number of viable cells in each sample.   
 
6.3.5  Measurement of Collagen Synthesis 
 Collagen synthesis of the cells was estimated by measuring the amount of Procollagen 
Type I C-peptide (PIP) levels in the medium with a commercially available ELISA kit (Panvera, 
Japan).  Medium samples collected at the end of the experiment were diluted (1:9) and processed 
according to the manufacturers instructions.  PIP is a propeptide that is cleaved from the 
procollagen secreted by the cells and reflects the stoichiometric amount of collagen synthesized.   
 
 
 
6.4  Results 
 
 
 
Generally, free-floating FPCGs without TGF-β treatment, used for control, showed a 
moderate decrease in gel area from 0 to 12h, followed by a sharp reduction in gel area from 12h 
to 24h.  From 24h to 48h, there was only a slight decrease in gel area.  FPCGs treated with TGF-
β3 contracted with a greater rate of gel area reduction from 0h to 12h.  Further, TGF-β1 
treatment resulted in a significant and steady reduction in gel area from 0h to 12h, before 
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approaching an equilibrium after 24h.  Overall, both TGF-β1 and TGF-β3 treatments resulted in 
a significant reduction in gel area at 4, 8, 12, 24, and 48h compared to control gel area, but TGF-
β1 caused a significantly greater reduction in gel area than TGF-β3 at 8, 12, 24, and 48h (Figure 
12).  Specifically, on average between 8 and 48 hours, the collagen gel area with TGF-β1 
treatment was 25.5% smaller than that with TGF-β3 treatment.  However, using the free-floating 
FPCG model, significant differences in the gel areas among the three dosages used (1, 5, and 25 
ng/mL) could not be established for either TGF-β1 or TGF-β3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12  TGF-β3 induces less HPTF contraction of a free-floating FPCG compared 
to TGF-β1 at 8, 12, 24, and 48 hrs (* p < 0.05). 
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Due to the inability of the free-floating FPCG model to detect the dose dependence of 
TGF-β1 and TGF-β3, the multi-station CFM system was used to monitor the effect of these 
growth factors on HSF contraction.  Visually, the cells deformed the sides of the gel into a 
parabolic shape (Figure 10), as a result of the near isometric tension in the FPCGs.  The 
deformation of the FPCG from the sides of the silicone dish allow for the detection of 
contraction forces.  Thus, any discrepancies in contraction forces measured by the CFM system 
may be attributed to the gel remaining attached to the silicone dish.  In the first experiment, 
control FPCGs, with HSFs in serum-free medium without TGF-β treatment, resulted in minimal 
contraction (~20 dynes) after about 18h.  However, HSFs treated with TGF-β1 (1, 5, and 25 
ng/mL) caused a marked increase in maximum contraction force (45, 60, and 45 dynes, 
Figure 13  Using the CFM system, all dosages of TGF-β1 were found to increase 
the maximum contraction force of the HSFs in a collagen gel compared to non-
treated controls.  The 5 ng/mL of TGF-β1 resulted in the largest increase in 
maximum contraction force (360% of control; black arrow), whereas 1 and 25 
ng/mL resulted in similar maximum contraction forces (280% of control). 
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respectively), as well as an earlier initiation of contraction (6.25, 5, and 7.5 h, respectively) 
(Figure 13).  The contraction patterns for each of the TGF-β1 dosages are similar, with 
differences in initiation of the FPCG contraction and the maximum contraction force.  Treatment 
with 5 ng/mL TGF-β1 resulted in the earliest initiation of contraction as well as the largest 
maximum force about 90 dynes (or 360% of control).  In addition, treatment with 1 ng/mL of 
TGF-β1 resulted in an earlier increase in contraction compared with 25 ng/mL.  Both dosages, 
however, resulted in about 70 dynes of maximum contraction force (280% of control) at 18h.  
Generally, a dose response to TGF-β1 treatment was observed, most noticeably affecting the 
initiation of contraction and the maximum force produced.  Based on the MTT assay, the control, 
1, 5, and 25 ng/mL TGF-β1 had similar cell activity (0.311, 0.373, 0.351, and 0.348 OD, 
respectively). 
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Similar to TGF-β1, the dosages of TGF-β3 (1, 5, and 25 ng/mL) also affected the 
initiation of contraction (6.5, 5.2, and 13 h, respectively) and maximum contraction force 
produced (15, 40, and -10 dynes, respectively) (Figure 14).  Further, treatment with 5 ng/mL 
TGF-β3 induced the earliest contraction (5.2h) and the highest maximum contraction force 
(180% of control) compared to the other dosages.  Although 1 and 5 ng/mL TGF-β3 increased 
HSF contraction, 25 ng/mL TGF-β3 actually inhibited contraction by delaying the initiation of 
contraction and resulting in a lower maximum contraction force, 80% of control.  The cell 
viability for the control, 1, 5, and 25 ng/mL TGF-β3 FPCGs were similar at the end of the 
experiment (0.233, 0.250, 0.268, and 0.265 OD, respectively). 
Figure 14  Using the CFM system, it was shown that TGF-β3 affected the initiation 
of contraction and the maximum force of contraction in a dose dependent manner.  
Specifically, similar to TGF-β1, 5 ng/mL of TGF-β3 resulted in the earliest 
contraction and the highest maximum contraction force (180% of control; black 
arrow). 
0
20
40
60
80
100
0 5 10 15 20
Time (hrs)
Fo
rc
e 
(d
yn
es
)
Control
1 ng/mL TGF
5 ng/mL TGF
25 ng/mL TGF
-β3 
-β3 
-β3 
   
  51 
 
With the treatment of either TGF-β1 or TGF-β3, similar shapes of contraction patterns 
were observed.  Also, although 5 ng/mL of both TGF-β1 and TGF-β3 resulted in the earliest 
contraction and the largest maximum contraction force compared to the other dosages, treatment 
with TGF-β1 caused about a 65 dyne increase in maximum contraction force (360% of control) 
compared to its respective non-treated control, whereas TGF-β3 resulted in only about a 40 dyne 
increase in contraction force (180% of control) compared to its non-treated control.   
 
Figure 15  PIP levels (columns) and maximum contraction force (lines) are 
apparently dosage dependent for both TGF-β1 and TGF-β3.  For both isoforms, the 5 
ng/mL dose resulted in the largest increase in PIP levels and maximum contraction 
force.  The trend for both collagen synthesis and maximum contraction force are 
similar for both isoforms, however, TGF-β3 increased PIP levels and maximum 
contraction force to a lesser degree than TGF-β1.  (n = 1 for all dosages) 
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Furthermore, the amount of PIP in the medium at the end of the experiment was 
measured using an ELISA kit.  It was found that the PIP levels followed a similar trend as the 
maximum contraction force for both TGF-β1 and TGF-β3, with 5 ng/mL of TGF-β treatment 
resulting in the largest PIP level increase, 752 and 599 ng/mL, respectively (Figure 15).   The 25 
ng/mL dosage for both TGF-β1 and TGF-β3 resulted in decreased PIP levels compared to 
control, -23 and -40 ng/mL respectively, whereas the 1 ng/mL TGF-β1 and TGF-β3 resulted in a 
605 and 373 ng/mL increase in PIP levels compared to control.   
 
Moreover, a similar dose dependent trend apparently exists between maximum 
contraction force and collagen synthesis.  For both the maximum contraction force and PIP 
levels, the 5ng/mL dose for either TGF-β1 or TGF-β3 resulted in the largest increase compared 
to the other dosages.  Further, for each dose, TGF-β1 treatment resulted in higher maximum 
contraction forces and PIP levels than TGF-β3.  In addition, 25 ng/mL of TGF-β1 resulted in 
about a 45 dyne increase in maximum contraction force compared to its control, however, PIP 
levels apparently returned to the control values.  In contrast, with 25 ng/mL of TGF-β3, both PIP 
levels and maximum contraction force returned to near control levels.  Further, a strong 
relationship exists between the level of PIP and maximum contraction force (Figure 16). 
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6.5  Discussion 
 
 
 
This study demonstrated that TGF-β1 and TGF-β3 treatments increase human fibroblast 
contraction in a collagen gel model, which is consistent with previous findings (18).  Moreover, 
this study quantify the effect of these growth factors on HSF contraction and indicate that TGF-
β1 increases cellular contraction to a greater degree than TGF-β3.  Although different systems 
were used to study cellular contraction, the HSFs and HPTFs responded similarly to the TGF-β1 
and TGF-β3 treatments in that TGF-β3 resulted in less FPCG contraction than TGF-β1.  Further, 
collagen synthesis, measured by PIP levels, followed a similar trend as the maximum contraction 
force, with apparent dose and isoform dependence.  Moreover, collagen synthesis and cellular 
Figure 16  Collagen synthesis and cellular contraction have an 
apparently strong relationship since PIP levels and maximum 
contraction force appear to have a linear relationship. 
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contraction appear to have a strong relationship.  In addition, it is worth discussing the variability 
of the controls for the TGF-β1 and TGF-β3 experiments, namely the different maximum 
contraction forces.  Based on the OD value from the MTT experiment, the cell densities are 
similar within each experiment, but are different between the two experiments.  This is most 
likely due to the controls being from two different experiments and the inherent variability in 
counting cells. 
 
Cellular contraction is known to be an important component of connective tissue wound 
healing (12,26).  The finding that both TGF-β1 and TGF-β3 increase cellular contraction of a 
collagen gel supports previous studies using skin fibroblasts (18).  Moreover, this study 
differentiated between the contractile forces induced by TGF-β1 or TGF-β3 using two different 
methods, a free-floating FPCG and a multi-station CFM system.  Although there were a limited 
number of samples, the effects of TGF-β1 and TGF-β3 were consistently demonstrated using 
two different models, as well as with fibroblasts from two different tissues.  Since excessive 
contraction is proposed to result in scar tissue formation (26) and TGF-β1 results in larger cellular 
contraction and collagen synthesis compared with TGF-β3, this may help to explain why TGF-
β1 induces scar formation whereas TGF-β3 reduces the formation of scar tissue (17).   
 
In agreement with literature, TGF-β1 and TGF-β3 differentially increased collagen 
synthesis of human skin fibroblasts (18).  For healing tissues, each of these cellular responses plays 
an important role in the wound healing process.  However, deviation from an optimal level for 
any of these cellular responses could adversely affect the quality and function of healing tissue.  
Therefore, as TGF-β1 was found to increase contraction and collagen synthesis of human skin 
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fibroblasts to a greater degree than TGF-β3, it is suggested that the lower cellular contraction and 
collagen synthesis induced by TGF-β3 may improve the quality of healing tissues. 
 
Although these findings are preliminary and further studies are required, they are 
consistent with literature.  Brown and coworkers also found that TGF-β1 and TGF-β3 were dose 
dependent, with moderate dosages (7.5 and 15 ng/mL) causing an optimal increase in human 
skin fibroblast contraction, whereas higher dosages (> 22.5 ng/mL) inhibited the cells 
contraction (60).  Moreover, using both the free-floating FPCG and the CFM system, TGF-β1 
consistently induced higher cellular contraction than TGF-β3.  Since cellular responses 
potentially translate to the tissue level, the differential induction of cellular contraction and 
collagen synthesis by TGF-β1 and TGF-β3 suggested by our findings may explain the 
differential effects seen in healing tissues with treatment with these two isoforms.  
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7.0  SUMMARY AND FUTURE DIRECTIONS 
 
 
 
The studies presented above are part of an overall objective, which is to reduce the 
formation of scar tissue by regulating cellular contraction.  The first study demonstrated that 
HPTFs are contractile and that the cells contraction depends on serum concentration.  In that 
study, the TSM and FPCG models were used to demonstrate the cells contraction, however 
these models were limited since they do not measure cellular contractile forces per se, and their 
sensitivity to detect small changes in cellular contraction forces is relatively low. 
 
To overcome these shortcomings, a multi-station CFM system was developed that uses 
semi-conductor strain gages to monitor beam bending due to force produced by CPCGs.  The 
current CFM system can measure four CPCGs simultaneously, which can be expanded for 
testing six CPCGs.  The semi-conductor strain gages used on the beams increase the sensitivity 
of the system since the gage factor is three to four times greater than conventional gages, which 
are commonly used in the other systems.  The multiple stations of this CFM system facilitate 
experimental designs and statistical analysis.  With this CFM system, contractile forces of 
HPTFs and HSFs were measured.  The results demonstrate that this system can differentiate 
between cells from different tissues by detecting differences in contraction patterns and 
maximum contraction force.  This finding also suggests that regulation of cellular contraction 
may need to be tailored to the targeted cells, since cells from different tissues have different 
contractile patterns and may respond differently to the same treatments. 
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Using the CFM system, the effect of TGF-β1 and TGF-β3 on human fibroblast 
contraction was also studied.  It was found that TGF-β1 induced higher cellular contraction force 
and collagen synthesis than TGF-β3.  Further, both TGF-β1 and TGF-β3 were shown to be dose 
dependent, with 5 ng/mL for both isoforms resulting in the highest cellular contraction force and 
collagen synthesis.  However, 25 ng/mL TGF-β1 caused a slight decrease in cellular contraction 
force but a substantial decrease in collagen synthesis compared to 5 ng/mL of TGF-β1, whereas 
25 ng/mL TGF-β3 caused a substantial decrease in both cellular contraction force and collagen 
synthesis compared to 5 ng/mL of TGF-β3.  Although future studies are underway to supplement 
these findings, certain dosages of TGF-β1 or TGF-β3 may be used to down-regulate fibroblast 
contraction and collagen synthesis and potentially reduce the formation of scar tissue.   
 
In spite of all these interesting findings, a couple of limitations exist in these studies.  
First, normal fibroblasts were used in each of these studies; however, healing fibroblasts will 
probably have different cellular contraction and collagen synthesis compared to normal 
fibroblasts.  To understand the differences between normal and healing fibroblasts, future studies 
will investigate the cellular contraction and collagen synthesis of healing fibroblasts with the 
CFM system.  A second limitation is the use of cells from only a single donor for each 
experiment.  On one hand, there is less variability when comparing between cells from the same 
donor; however, on the other hand, it remains to be established as to whether these effects are 
reproducible with cells from other donors.  Future studies will use cells from different donors in 
an effort to supplement the existing data and demonstrate the reproducibility of these findings. 
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Several future studies are also underway to further investigate cellular contraction using 
this CFM system.  One study is investigating the effect of prostaglandin E2 (PGE2), an 
inflammatory mediator of tendons (62), and hydrocortisone, which can reduce the formation of 
PGE2, on HPTF contraction and collagen synthesis.  The presence of PGE2 in injured tendons, 
e.g. tendonitis, may affect the contraction of the tendon fibroblasts and the healing of the tendon.  
Preliminary data indicate that PGE2 inhibits HPTF contraction of FF-FPCGs, whereas 
hydrocortisone increases HPTF contraction (Figure 17 in the Appendix).  Thus, certain levels 
of PGE2 may regulate tendon fibroblast contraction; however, if levels of PGE2 are further 
elevated, this may further reduce tendon fibroblast contraction and impair the wound healing 
process.  Understanding the effects of PGE2 on cellular responses, e.g. cellular contraction and 
collagen synthesis, will help determine its role in tendon healing, as well as potential methods to 
regulate cellular contraction.  The second study addresses a fundamental research question in our 
overall objective:  Do healing fibroblasts contract more than normal fibroblasts?  In fact, healing 
fibroblasts from rat medial collateral ligaments (MCLs) were found to contract to a greater 
degree than those from normal rat MCLs (Figure 18 in the Appendix).  As the preliminary 
findings for both of these studies are encouraging, additional experiments will be performed to 
confirm these findings.  Lastly, since the ratio of TGF-β1 and TGF-β3 is proposed to be 
important in regulating scar formation (59), a future study will investigate the combination of 
TGF-β1 and TGF-β3, in different ratios, on cellular contraction and collagen synthesis to 
understand the combined effect of these growth factors.  Therefore, by regulating the degree of 
cellular contraction with treatments such as TGF-β3, formation of scar tissue in healing tissues, 
i.e. skin, tendons, and ligaments, may be reduced. 
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With the newly developed multi-station CFM system, there are many potential 
applications for future research investigating the role of cellular contraction in tissue wound 
healing.  Using this system, contraction patterns of different cell types can be studied to 
determine how to optimally regulate the cells contraction in order to reduce the formation of 
scar tissue.  Although additional studies are needed, the findings in this thesis suggest that TGF-
β3 may be used to regulate contraction and collagen synthesis of human skin and tendon 
fibroblasts, potentially reducing the formation of scar tissue.  Moreover, the knowledge acquired 
by these studies can be used to investigate contraction of other cell types, such as endothelial 
cells, and determine the role of the cells in tissue healing.   
 
Further, with use of the CFM system, future studies will focus on the healing mechanisms 
of tendons and ligaments, particularly focusing on the effect of growth factors, such as TGF-βs, 
platelet derived growth factor, endothelial growth factor, etc., on cellular contraction and 
collagen synthesis.  However, the relationship of cellular contraction to other cellular responses 
important during wound healing, i.e. collagen synthesis, also remains to be investigated.  These 
studies will help define the role of cellular contraction in tissue wound healing, and potentially 
lead to advanced treatments that target cellular contraction and subsequently improve the quality 
of healing tissue. 
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APPENDIX
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Experimental Protocols 
 
 
 
 
Preparation of TSMs 
 
 
 
1. Hold a 25x25 mm (or 25x 50mm) cover slip with tweezers at one corner of the cover slip. 
2. Use a scoop to place silicone (Wacker Silgel 601A) onto the top of the cover slip (spread 
the silicone over the entire cover slip, except for the corner where you are holding the 
cover slip, and dont use too much). 
3. Turn the cover slip upside down, so that the silicone is on the bottom surface. 
4. Hold it briefly over a bunsen burner flame (hold over the flame just long enough so that 
you see the surface glaze over, about 2 seconds). 
5. Turn the cover slip right side up (with the silicone on the top surface). 
6. Carefully place inside a petri dish without disrupting the membrane (if silicone flows out 
onto the petri dish, you will need to remake the TSM). 
7. Place a small amount of Medical Adhesive Silicone Type onto the corner without any 
silicone (where you held the cover slip with the tweezers), being careful not to disrupt the 
membrane by touching it. 
8. Leave the petri dish uncovered and expose the membrane to UV light for 1 hour. 
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Plating cells on TSMs 
 
 
 
1. Make a fresh batch of pronectin. 
2. Carefully pipette the pronectin to the side of the cover slip so that the pronetin gently 
overflows onto the silicone membrane.   
3. Leave the pronectin sit on the membrane for ten minutes.   
4. Extract the pronectin with a pipette, to the side of the cover slip. 
5. Wash the membrane twice with PBS by the same overflow method used above 
(extract the PBS by the same means as above). 
6. Cover the petri dishes and allow the membranes to dry before adding cells (place in 
incubator if necessary). 
7. Count the cells and dilute to a cell concentration of 7x104 cells/mL. 
8. Add 1 mL of the 7x104 cells/mL cell solution to the 25x50 cm2 cover slip and 0.50 
mL to the 25x25 cm2 cover slip. 
9. Incubate for 1 hour at 37oC to allow cells to attach. 
10. Check cell attachment. 
11. Once cells are attached, add media so that the membrane is completely covered.   
12. Place cells into 37oC incubator and maintain cells. 
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Preparation of Free Floating-FPCGs 
 
22 m m Cell Type:
# of wells w ith gels: 33
# of wells w ith cells: 30 Donor:
Desired cell density: 500,000 cells /m L Passage used:
Total grow th m edia needed: 54.000 m L Date last split:
Total volum e of cells  needed: 9.000 m L
Total collagen solution needed: 16.500 m L Initia ls:
Total cell num ber: 4,500,000 cells G M : AIM -V m edia w ith 1%  P/S
Cell density: 395 cell/m m ^2
Collagen solution density: 2.560 m g/m L
Collagen Solution Add: 1.700 m L 10X PBS
1.700 m L 0.1 M  NaO H
13.600 m L Collagen Solution 3.2 m g/m L
M ade: 17.000 m L
M ix w ith pipette.
Check pH.  Should be between 7.0 and 7.5 (a dark green color - see indicator).
pH  indicator:
P lace in refrigerator (tim e):
Keep refrigerated for at least 2 hours.
Collagen solution at Rm  Tem p:
Cell Preparation Extract m edia.
Add 3 m L of trypsin to each dish.
Incubate for ~3 m in. or until cells are detached.
Add 5 m L of DM EM  (10%  FBS, 1%  P/S ) per d ish.
P ipette into conical tube.
Centrifuge at 1000 RPM  for 5 m in.
Extract supernatant.
Add G M  to count cells .
Cell count (d ilute to 500,000 cells/m L):
Total volum e needed:
Current volum e:
Volum e of G M  to be added:
Seeding cells on co llagen  gel To each well of an untreated 12-well p late add:
22 m m
0.300 m L Cells (500,000 cells/m L)
0.500 m L Collagen solution
M ix and rem ove bubbles.
Incubate at 37 C , 5%  CO 2 (for about 30 m in).
P laced in incubator at:
After 30-45 m inutes, to each well add:
22 m m
1.500 m L G M  (+condition)
Tap bottom  of d ish to detach gels
Returned to incubator at:
W ell D iam eter
W ell D iam eter
W ell D iam eter
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Measuring FPCG Contraction with the CFM System 
 
 
 
1. Prepare incubator 
a. Fill water pan 
b. Clean CFM and shelves 
c. Make sure beam and tension unit attachments are set up properly 
2. Check cells so that they are ~80% confluent 
3. Clean and autoclave: 
a. Silicone dishes 
b. Gel attachment units 
4. Warm medium and trypsin 
5. Keep autoclaved parts (#3) in incubator to warm them to temperature 
6. Make collagen gel solution, mix well, and place in 4°C until needed 
a. For 4 gels (mix in 50 ml conical tube): 
i. 2.2 ml of 10x PBS 
ii. 2.2 ml of 0.1 M NaOH 
iii. 17.4 ml collagen stock solution (Vitrogen, 0701 FXP-019) 
7. Setup computer and data acquisition system 
a. Turn on power supply and check excitation voltage with volt meter (this will 
allow strain gages to get to temperature) 
b. Open CFM experiment and CFM set-up programs 
c. Change path to C:\WINDOWS\Desktop\CFM [cell type] [date].txt, i.e. 
C:\WINDOWS\Desktop\CFM HPTF 032402.txt 
8. Prepare cells: 
a. Extract medium from petri dish 
b. Add 3 ml of trypsin to cells and place in incubator for about 2 minutes 
c. Check cells, via light microscope, to ensure that they are unattached (tapping the 
bottom of the petri dish can loosen some cells as well) 
d. Add 5 ml of growth medium (with 10% FBS) to counter the trypsin 
e. Using a pipette, tilt the petri dish and wash cells to the bottom 
f. Pipette the cells into an appropriate sized conical tube (15 or 50 ml) 
g. Centrifuge the cell solution (1000 RPM for 5 minutes); prepare hemacytometer 
while waiting for the centrifuge 
h. Extract the supernatant, leaving the cell pellet and a small amount of solution, try 
not to loose cells 
i. Add a small amount of the medium that will be used in the experiment, depending 
on the desired density, and mix well 
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j. Count cells with hemacytometer 
i. Clean and dry hemacytometer 
ii. Place cover slip on hemacytometer 
iii. Obtain 10 µl of well mixed cell solution and pipette onto hemacytometer 
iv. Count the four corners and find the total number of cells per 
ml=(C1+C2+C3+C4)x104/4 (cells/ml) 
v. Dilute cell solution to appropriate density 
9. Set out collagen solution while waiting for the centrifuge 
10. Prepare dishes and gel attachment units so that FPCG solution can be added 
11. Mix: 
a. Desired cell density 66.66 (=2x106 cells/gel) 
b. 13.2 ml cells to the 22 ml collagen 
12. Pipet 8 ml of mixture into silicone dish and between vyon bars 
13. Incubate for 10 minutes 
a. While waiting, start CFM program on computer 
14. Add 7ml of appropriate growth medium (AIM-V with TGF-β1 or 3) 
15. Label gels 
16. Attach to CFM and provide initial tension (check by seeing ~2-3mV increase) 
17. Make sure everything is running properly and clean up 
a. Properly dispose of all used materials, including cells, into biohazard waste 
receptacle 
b. Wash hood down with ethanol 
c. Clean hemacytometer and cover slip with ethanol 
18. Obtain 100 µl of medium from each sample for the procollagen assay 
19. Let experiment run for the designated time 
20. Collect 100 µl of medium at the end of the experiment 
21. Perform MTT assay 
a. Note:  after 3h incubation, use chemidoc system to take pictures of the contracted 
gels 
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Measuring Cell Viability with MTT Assay 
 
 
 
For FF-FPCG: 
1. Add 200 µL MTT solution to each FF-FPCG 
2. Incubate for 3h 
3. Centrifuge plate of FF-FPCG 1900 RPM for 5 minutes 
4. Remove supernatant 
5. Add 2 mL extraction buffer 
6. Incubate overnight 
7. Add 20 mL DI H2O (1:5 dilution) 
8. Add 200 µL to 96 well plate (run in duplicates) 
9. Read plate at 550 nm using microplate reader (SpectraMax 190, Molecular Devices) 
 
For FPCG in the CFM System: 
1. Add 500 µL MTT solution to each FPCG (leave attached to CFM) 
2. Incubate for 3h 
3. Detach FPCG from CFM 
4. Transfer FPCG to 50 mL conical tube 
5. Centrifuge 1900 RPM for 5 minutes 
6. Remove supernatant 
7. Add 4 mL extraction buffer 
8. Incubate overnight 
9. Add 20 mL DI H2O (1:5 dilution) 
10. Vortex 
11. Add 200 µL to 96 well plate (run in duplicates) 
12. Read plate at 550 nm 
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Multi-Station CFM System:  Parts List 
 
 
 
Item Description Vendor Catalog # Price/ea 
Semi-
conductor 
strain gages 
Mounted on beams to 
measure beam bending 
Micron 
Instruments 
G150786 $160.60 
Support rod Hard aluminum rod- 
12 long, 0.5 diam 
Fisher Scientific 14-666-10G $7.55 
Support rod Hard aluminum rod  
18 long, 0.5 diam 
Fisher Scientific 14-666-10B $8.78 
Rod 
Connectors 
90° angle, 0.5 hole, 
castaloy metal 
Fisher Scientific 14-666-20 $6.93 
CFM base 
and fixation 
units 
Aluminum 
base/fixation units and 
25 hours of labor 
School of 
Engineering 
Machine Shop 
 $854.50 
Beam clamps Stainless steel beam 
clamps (4) and 5 hours 
of labor 
School of 
Engineering 
Machine Shop 
 $165.75 
Strain gage 
wire 
100 wire to wire gages 
to connector block 
Measurements 
Group 
426-DFV  
Wire frames 
(gel 
attachment 
units) 
0.014 diameter wire, 
Stainless steel type 304 
V wire 
Small Parts.com U-SWGX-
140 
$1.70 
DAQ card  
6024E 
PCMCIA DAQ card 
with digital triggering, 
two analog outputs, 
two counter/timers, 
eight digital I/O lines 
National 
Instruments 
778269-01 $625.50 
Shielded 
cable 
Cable for connecting to 
connector block 
National 
Instruments 
186838-02 $99.00 
Shielded 
connector 
block 
Block connecting CFM 
and voltage source 
(SCB-68) 
National 
Instruments 
776844-01 $265.50 
IBM 2628 
notebook 
550 
MHz/6GB/64MB/12.1 
TFT/Win98  
TigerDirect.com M975-
26281UU 
$799.99 
Vyon bars Attachment area for the 
gel  
Porvair, Inc.  Sample 
Silicone 
dishes 
Cells and collagen gels 
placed inside 
  Made in the 
lab 
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Data Acquisition Program (Labview 5.1) for Monitoring Cellular Contraction 
 
 
 
 
Summary:  Program overview 
 
 
 
The LabView program for the CFM was designed to display and record the signal voltage from 
the semiconductor strain gages. Further, the user can define the number of data points sampled, 
as well as the time interval over which the data points are collected.  This program consists of a 
combination of for loops and while loops with sequence structure frames used to separate 
the data acquisition program and the delay.  For Loop A allows the user to specify the number 
of times the entire program runs before stopping.  The program is set to run 200,000,000 times, 
an arbitrarily large number so that the user is able to end the program at the end of the 
experiment before the program terminates itself.  Within the first sequence structure, Frame 1, 
For Loop B allows the user to specify the number of data points to be recorded per run through 
the program.  The portion of the program that records the voltage signal from the strain gages is 
located in While Loop C.  This allows for the continual running and specification of the 
sampling rate for recording the data.  The next frame in the sequence structure, Frame 2, 
contains the program delay.  This delay is user specified on the data screen in minutes, default 
delay set to 10 minutes.  When the data is recorded from the system, it is automatically saved to 
the user specified location in the Microsoft Excel format (*.xls).  The user is also able to input 
the upper and lower voltage limits on the front panel, which can change the resolution of the data 
acquisition system, therefore, it should usually be left at the default setting.  The program is 
designed to record as many as eight channels at a time (1 channel/bar); however, only those 
channels specified are recorded.  The default setting for the program is to use Device 1 and 
record channels 1, 2, 3, and 4.         
 
 
 
 
Code Descriptions:  Code used in the program 
 
 
 
1. Sequence Structure  This function allows for the recording of data from the strain gage 
in Frame 1 followed by a delay in Frame 2. 
 
2. For Loop(s) -  Two for loops exist in the program.  The outermost for loop,  For 
Loop A, allows the user to specify the number of times the program should run through 
the entire program.  The second for loop,  For Loop B, allows the user to specify the 
number of times Frame 1 should run before continuing to Frame 2 for the delay.  The 
default value of the outermost for loop is currently 200,000,000, an arbitrary large 
number so that the program may run continuously until user manually stops the program, 
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and the default value for the innermost for loop is 100 iterations which corresponds to 
the number of samples taken each time through the program.  The user is able to define 
the number of iterations that are desired at each time point.  
 
3. While Loop  The while loop, While Loop C, allows the program in Frame 1 to run 
continuously for the number of specified times in the for loop.  After each run through 
the while loop, the signal voltage is recorded. 
 
4. High/Low Limits  These are the limits that the program has set when recording the 
data.  The user is able to specify these numbers on the front panel of the program.  The 
default setting is a low limit of 0.0 and a high limit of 0.01.  Changing these values will 
change the gain of the data acquisition card. 
 
5. Delay Timer  The delay in Frame 2 of the sequence structure is set up to take the user 
input time delay value from the front panel of the diagram and multiply it by 60000 to 
convert the entered minute value into milliseconds.  The delay is not 100% accurate.  The 
delay can be slightly more or less than the specified time in milliseconds.  This 
discrepancy does not affect the overall value of the delay, however, since the value varies 
on a millisecond level. 
 
6. Time Stamp  As each data point is recorded, the time that the data point is recorded is 
also saved in another sheet that the user is able to specify. 
 
7. Save to File Function  This function allows the user to save the data that is read to a 
specified file on the computer.  The True/False statement included with this function tells 
the program to add each subsequent data point to those previously recorded without 
writing over the data points.  The statement should always be true in order to record 
without writing over the previous data.  The user is able to specify where the data will be 
saved on the front panel of diagram.  The current default setting is for the data to be 
saved as a Microsoft Excel file on the computer desktop with the file name being test.  
An example of the name appearing on the front panel is C:Window/Desktop/test.xls.  The 
default setting is currently at three decimal places for each data point.  The setting for the 
decimal places can be changed by adjusting the numeric value associated with the 
function located as a numeric constant wired to the function.   
 
8. Analog Input  This function records the signal read by the channels specified by the 
user on the front panel of the diagram.  This function in particular, allows for loop 
iterations to record multiple data over a period of time, as well as the specification of 
various other aspects.  The data is recorded as 1D array, which is then saved to the hard 
disk and graphed on the front panel.  The high and low input limits are specified allowing 
for more precision in the answer.   
 
9. Array to Graph  With the data being continuously recorded, it is important to see the 
general trend that is occurring through each iteration of the frame.  Only those channels, 
which are specified, are plotted on the graph, and each channel is plotted as a different 
color.  The current values that are being recorded are also placed next to the graph in a 
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table format with a precision of three decimal places.  The recorded value from the 
analog input function is multiplied by 1000.  This allows for the conversion of volts to 
millivolts for easier numbers to work with for the experiment. 
 
 
 
 
Program Functions:  Understanding the code 
 
 
 
1. Channel Monitoring  The embedded program/sub VI, channel name to string array, 
was designed for the specific purpose of monitoring the specified channels.   
 
2. Time Stamp  Defines the time at which each sample was taken for reference. 
 
3. Delay  In order to obtain a delay in the program, a sequence structure is used.  With this 
structure, the program is unable to go from Frame 1 to Frame 2 without first completing 
the desired number of iterations in Frame 1.  Frame 2 holds the delay portion of the 
program.  LabView has a wait function available that counts in milliseconds.  This 
function was easily used for the program by incorporating a multiplication factor in order 
to change the delay time in minutes to milliseconds for the function to understand.  When 
the time is changed from minutes to milliseconds, some discrepancy may arise, but the 
discrepancy will be in milliseconds making any difference inconsequential to the delay 
time. 
  
4. Inputs There are a number of user specified inputs on the front panel.  The following 
lists each individual input, its function, and default value. 
 
! Device  The default value is set to 1.  This is a constant numeric value because 
the device is always located at 1.  If multiple devices are used by the same 
computer there may then be other device numbers. 
! Voltage Limits  Both the High and Low voltage limits are input by the user.  
These limits set the gain of the strain gages adjusting the resolution of the voltage 
recorded.  The default values are 0.00 and 0.10 for the low and high limits, 
respectively.   
! Channels  These are the channels that are reading the voltages from the stain 
gages.  The default values are 1, 2, 3, and 4.  The program can record up to 8 
channels in the differential mode.  Provided that the proper wires are connected to 
the proper channels, any 4 channels could be chosen.  In this experiment, the 
wires are connected to the four previously specified channels. 
! Sampling Rate  This refers to the number of samples taken for a given time 
frame.  The sampling rate is set at 10 sample/ 1 sec, i.e. 10 Hz.  This value allows 
the user to take 100 samples every 10 seconds, the desired number of samples for 
this project.   
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! Delay  This value was discussed above.  As stated above the input value is 
entered as the number of minutes the program should delay.  The default value is 
set to 10 minutes.   
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PGE2 Reduces whereas Hydrocortisone Increases HPTF Contraction of a Collagen Gel 
 
 
 
Figure 17  PGE2 significantly inhibited HPTF contraction of a collagen 
gel at 6, 8, 12, and 24h compared with untreated controls and treatment 
with hydrocortisone (HC). 
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Contraction of Normal and Healing Rat MCL Fibroblasts 
 
 
 
 
 
Figure 18  Healing and normal rat MCL fibroblasts have similar initial contraction 
rates, however, the healing fibroblasts contract with a greater maximum force than the 
normal fibroblasts.   
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